儿童近视控制的局部阿特罗平:阿特罗平治疗长期评估研究
Yong Li1,2, Michelle Yip1, Yilin Ning2
1Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
JAMA ophthalmology
|November 29, 2023
概括
长期随访儿童近视控制局部氨酸 (0.01%-1.0%) 没有显著差异折射误差或眼部并发症治疗后的几年. 需要进一步研究近视管理的最佳阿特罗宾度和持续时间.
科学领域:
- 眼科医生 眼科 眼科
- 儿科眼科医生 儿科眼科医生
- 临床研究 临床研究
背景情况:
- 局部阿特罗平眼滴用于儿童近视控制,但长期安全性和有效性数据有限.
- 之前的短期研究报告了关于阿特罗宾在近视管理中的有效性不一致的结果.
研究的目的:
- 为了评估儿童近视控制的长期安全性和结果,使用局部氨酸.
- 评估眼部并发症的发生率和长期随访后折射误差的变化.
主要方法:
- 一项前性,双面罩的观察性研究,分析了来自Atropine for the Treatment of Myopia (ATOM) 1和ATOM2试验的数据.
- 成年参与者从ATOM1 (1%的阿特罗宾与安慰剂) 和ATOM2 (0.01%,0.1%,0.5%的阿特罗宾) 被审查了治疗后10-20年.
- 主要结果指标包括循环的球体等价值 (SE) 和轴长 (AL) 的变化,以及眼部并发症的发生率.
主要成果:
- 在被评估的参与者中,在阿特罗平治疗组和安慰剂之间没有观察到最终折射误差 (SE) 或轴长 (AL) 的显著差异.
- 白内障/透镜不透明的发生率,近视性黄斑变性,和 parapapillary 缩在1%的阿托和安慰剂组之间没有差异.
- 长期跟踪 (10-20年) 儿童类药物治疗 (0.01%-1.0%) 没有显示增加的眼部并发症.
结论:
- 短期使用局部阿特罗宾用于儿童近视控制 (0.01%-1.0%) 与折射误差或主要眼部并发症的长期差异无关.
- 研究结果表明,需要进行更长期的研究,以确定近视管理的最佳阿特罗宾度和持续时间.
- 长期来看,阿特罗宾对近视控制的安全性概况似乎有利,但需要对治疗参数进行进一步的研究.
相关概念视频
01:27Open Angle Glaucoma: Treatment
456
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
456
01:28Angle Closure Glaucoma: Treatment
515
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
515
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
756
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
756
01:24Cholinergic Antagonists: Pharmacokinetics
460
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
460
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
684
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
684